We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
(Approval lapsed) Capecitabine Tablets USP 500mg (Camber Pharmaceuticals, USA)
Section 19A approved medicine
(Approval lapsed) Capecitabine Tablets USP 500mg (Camber Pharmaceuticals, USA)
Section 19A approval holder
Pro Pharmaceuticals Group ABN 20 605 457 430
Phone
1300 077 674
Approved until
Status
Expired
Medicines in short supply/unavailable
Capecitabine Sandoz capecitabine 500mg film coated tablet blister pack - ARTG 201800
XELABINE capecitabine 500 mg film-coated tablet blister pack - ARTG 213045
XELABINE capecitabine 500 mg film-coated tablet blister pack - ARTG 213045
Indication(s)
Colon Cancer:
- Capecitabine is indicated for the adjuvant treatment of patients with Dukes' stage C and high-risk stage B, colon cancer, either as monotherapy or in combination with oxaliplatin.
Colorectal Cancer:
- Capecitabine is indicated for the treatment of patients with advanced or metastatic colorectal cancer.
Oesophagogastric Cancer:
- Capecitabine is indicated for the first-line treatment of patients with advanced oesophagogastric cancer in combination with a platinum-based regimen.
Breast Cancer:
- Capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. Capecitabine in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.
Images
